Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Journal of the American Academy of Dermatology | Sep 10, 2021
Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines
Journal of the European Academy of Dermatology and Venereology | Sep 05, 2021
Most read this week